A Troubleshooting Guide for Topical Drug Manufacturing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

A Troubleshooting Guide for Topical Drug Manufacturing
Consider critical process parameters and strategies to optimize the manufacturing process

Pharmaceutical Technology
Volume 36, Issue 11, pp. 46-49

Incorporate QbD

Table I: A design of experiments was conducted to determine how the final viscosity of a formula varied based on the amount of shear and temperature during which the shear is applied. Emulsification rate was held constant at high rpm.Emulsification temperature was held constant at 75–80 C. Emulsification time and the rate of low-shear mixing were varied. The goal was to produce the highest product viscosity; the higher rate of shear yielded the best results.
Implementing a quality-by-design (QbD) approach to developing CPPs has become a necessity. Most notably, a design of experiments (DOE) can be used to gain an understanding of what processing parameters have the greatest impact on the critical quality attributes of the final product. This understanding can be used to implement a chemistry, manufacturing, and controls (CMC) strategy to ensure stability, product performance, and process control in manufacturing a topical drug product. A DOE, for example, was conducted to determine how the final viscosity of a formula varied based on the amount of shear and temperature during which the shear is applied. The goal was to produce the product with the highest viscosity. As shown in Table I, the higher rate of shear yielded the best results.

Use process-control tools

Even though preserved, topical formulations do not require the strict process controls required in sterile manufacturing, topical formulations must still have a well understood and controlled process. Emulsions, for example, can be difficult to process because they are inherently thermodynamically unstable. The use of manufacturing vessels with programmable logic controllers (PLCs) is one tool that can provide more reliable and accurate control of the pressure/temperature and mixing speed and times.

Add ingredients in the optimal phase and order

Generally, topical formulations comprise one or more phases. Emulsions, for example, primarily comprise an aqueous phase and a hydrophobic phase. Adding ingredients in the correct phase contributes to overall stability. For example, some polymers, such as microcrystalline cellulose/sodium carboymethylcellulose, must be dispersed and hydrated prior to adding other ingredients.

Most ingredients have an optimal method of incorporation into a formulation. Preservatives, such as parabens, should be added just prior to emulsification to reduce time in contact with water-soluble surfactants at elevated temperatures. Polymers (e.g., carbomer) and gums (e.g., xanthan) must be added slowly to avoid formation of fish eyes and other partially hydrated, undispersed material. These problems can be avoided by using eductors (e.g., Tri-Blender and Quadro Ytron dispersers) or by preparing a slurry of polymer or gum in a medium of low or no solubility (e.g., glycerin or glycols for certain gums or oils for carbomers). These thickeners act as emulsion stabilizers to keep oils or creams suspended in water and prevent separation. Such thickeners can be shear sensitive, however, so they must be processed with care.

As an example, DPT Labs was tasked with manufacturing a formulation that was a fatty-acid-based emulsion neutralized using an amine. With the amine in the water phase upon emulsification, the product immediately gained viscosity, requiring a higher mixing speed. As the product cooled, the formulation hit a critical temperature in which it rapidly thinned out and began splashing out of the mixing tank. Resequencing the product and adding the amine post-emulsification, however, maintained the quality of the product and eliminated negative effects on the formulation and potential danger to staff.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here